Select Region or Location
Americas
  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • Other Americas
Europe
  • Austria
  • Belgium
  • Bulgaria
  • Croatia/Hrvatska
  • Cyprus
  • Czech Republic
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovak Republic
  • Slovenia
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Kingdom
  • Other Europe
Asia Pacific
  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Korea, Republic of
  • Malaysia
  • New Zealand
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Other Asia Pacific
Africa And Middle East
  • Egypt
  • Israel
  • Other Africa And Middle East
USD
Home Cart Sign in  
Chemical Structure| 15884-86-3 Chemical Structure| 15884-86-3

Structure of 15884-86-3

Chemical Structure| 15884-86-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only! Not for Human Use. We Do Not Sell to Patients.

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]}{[ size_append_text(item.pr_size, proInfo.prAm, 'list') ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}
    {[ size_append_text(item.pr_size, proInfo.prAm, 'list') ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 15884-86-3 ]

CAS No. :15884-86-3
Formula : C4H7N3OS
M.W : 145.18
SMILES Code : NC1=NN=C(COC)S1
English Name :5-(Methoxymethyl)-1,3,4-thiadiazol-2-amine
MDL No. :MFCD01203002
InChI Key :ZLDOCTTXAVVDHG-UHFFFAOYSA-N
Pubchem ID :660844

Safety of [ 15884-86-3 ]

Computational Chemistry of [ 15884-86-3 ] Show Less

Physicochemical Properties

Num. heavy atoms 9
Num. arom. heavy atoms 5
Fraction Csp3 0.5
Num. rotatable bonds 2
Num. H-bond acceptors 3.0
Num. H-bond donors 1.0
Molar Refractivity 35.17
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

89.27 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.15
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

-0.3
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

0.12
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-1.12
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.3
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.23

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-0.83
Solubility 21.5 mg/ml ; 0.148 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.11
Solubility 11.2 mg/ml ; 0.0768 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.07
Solubility 12.3 mg/ml ; 0.0845 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-7.4 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

2.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.87

Application In Synthesis of [ 15884-86-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 15884-86-3 ]

[ 15884-86-3 ] Synthesis Path-Downstream   1~14

YieldReaction ConditionsOperation in experiment
Thiosemicarbazid/Methoxyessigsaeure;
Thiosemicarbazid, Methoxyessigsaeure/POCl3;
With sulfuric acid at 80 - 90℃; Cooling with ice; 1 General procedure: Add 0.3 mol acetic acid and 0.25 mol thiosemicarbazide into a 250 mL single-neck round bottom flask.Slowly add 31.5 mL of concentrated sulfuric acid dropwise while stirring in an ice bath (complete the addition within 30 minutes). Then the reaction was stirred to room temperature, and then slowly heated to 80-90°C for 7 hours. After the reaction solution is cooled to room temperature, slowly pour it into 500 mL of ice water. A large amount of colorless solid will form. Filter and wash the filter cake with cold water until neutral. Collect the filter cake, dry it with an infrared lamp, and then recrystallize it with ethanol to obtain 2-amino-5-methyl-1,3,4-thiadiazole. The preparation process of other such compounds is the same as that of 2-amino-5-methyl-1,3,4-thiadiazole. The structure and NMR data of this intermediate are shown in Table 1 below:
With sulfuric acid at 80 - 90℃; Cooling with ice; 1 General procedure: Add 0.3 mol acetic acid and 0.25 mol thiosemicarbazide into a 250 mL single-neck round bottom flask.Slowly add 31.5 mL of concentrated sulfuric acid dropwise while stirring in an ice bath (complete the addition within 30 minutes). Then the reaction was stirred to room temperature, and then slowly heated to 80-90°C for 7 hours. After the reaction solution is cooled to room temperature, slowly pour it into 500 mL of ice water. A large amount of colorless solid will form. Filter and wash the filter cake with cold water until neutral. Collect the filter cake, dry it with an infrared lamp, and then recrystallize it with ethanol to obtain 2-amino-5-methyl-1,3,4-thiadiazole. The preparation process of other such compounds is the same as that of 2-amino-5-methyl-1,3,4-thiadiazole. The structure and NMR data of this intermediate are shown in Table 1 below:

  • 2
  • [ 79-19-6 ]
  • [ 13779-42-5 ]
  • [ 625-45-6 ]
  • [ 15884-86-3 ]
YieldReaction ConditionsOperation in experiment
56 EXAMPLE 56 EXAMPLE 56 Addition of phosphonyl chloride to a mixture of thiosemicarbazide and methoxyacetic acid at 60°-95° and working up of the product yields 5-amino-2-methoxymethyl-(1,3,4)-thiadiazole, m.p. 177°-179° (from water).
86 EXAMPLE 86 EXAMPLE 86 Addition of phosphonyl chloride to a mixture of thiosemicarbazide and methoxyacetic acid at 60°-95° and working up of the product yields 5-amino-2-methoxymethyl-(1,3,4)-thiadiazole, m.p. 177°-179° (from water).
  • 3
  • [ 79-19-6 ]
  • [ 625-45-6 ]
  • [ 15884-86-3 ]
YieldReaction ConditionsOperation in experiment
89% With trichlorophosphate In 1,4-dioxane at 70 - 80℃; for 6h; Large scale;
81% With trichlorophosphate In 1,4-dioxane at 20 - 80℃; for 1.5h; 2.1 Synthesis of 5-(methoxymethyl)-1 ,3,4-thiadiazol-2-amine a25.To a suspension of thiosemicarbazide a24 (40 g, 0.44 mol, 1 eq) in dioxane (400 ml) at room temperature is added methoxyacetic acid (39.56 g, 0.44mol, 1 eq) in one portion, and the reaction mixture is heated at 80°C then phosphorous oxychloride (67.54 g, 0.44 mol, 1 eq) is carefully added over 1.5 hours. After reaction completion (4 hours), water is added and the solution is neutralised to pH=6-7 with sodium hydroxyde pellets. After extraction EtOAc/iPrOH (9/1 ) and evaporation under vacuum, the residue is recrystallized from MeTHF/iPrOH to afford 51 g of pure 5-(methoxymethyl)-1 ,3,4- thiadiazol-2-amine a25.Yield: 81 %. LC-MS (MH+): 146.
With sodium hydroxide; trichlorophosphate In water monomer; Petroleum ether 6.a EXAMPLE 6 a. Phosphoryl chloride (87 ml) was added dropwise to a vigorously stirred mixture of thiosemicarbazide (100 g), methoxyacetic acid (100 g) and petroleum ether b.p. 80°-100° (200 ml) maintained at 60°-70°. The temperature of the mixture was slowly raised to 95° and was kept at this temperature until the evolution of gas ceased. The solvent was evaporated and the residual syrup was dissolved in water (200 ml) to give a yellow solution which was adjusted to pH 7 by the addition of 10N NaOH. The mixture was filtered to give 5-amino-2-methoxymethyl-(1,3,4)-thiadiazole (111.25 g). Recrystallisation from water gave compound with m.p. 177°-179°. (Found: C, 32.9; H, 4.8; N, 29.1; S, 22.0; C4 H7 N3 OS requires: C, 33.1; H, 4.9; N, 29.0; S, 22.1%).
With trichlorophosphate at 75℃; for 1h; 4.1.2. General procedure for the preparation 5-substituted-1,3,4-thiadiazol-2-amines 4a-4f General procedure: To a round-bottom flask were added thiosemicarbazide (10 mmol,1.0 eq.), carboxylic acid (11 mmol, 1.1 eq.) and POCl3 (5 mL). The resulting mixture was heated to 75 °C and stirred for 1 h. The reaction mixture was then cooled to room temperature, to which tepid water(10 mL) was slowly added, and it was further heated to reflux and stirred for 1 h. After cooling, the reaction mixture was neutralized with 50% NaOH and the precipitated solid was collected by filtration and washed with water. The crude product was then recrystallized from ethanol. Yield 70-80%.

  • 4
  • [ 15884-86-3 ]
  • [ CAS Unavailable ]
  • [ 61450-91-7 ]
YieldReaction ConditionsOperation in experiment
With hydrogen bromide; copper(I) bromide; sodium nitrite 6.b EXAMPLE 6 b. An intimate dry mixture of 5-amino-2-methoxymethyl-(1,3,4)-thiadiazole (34.8 g) and sodium nitrite (75.9 g) was added over 1.5 hours to a stirred mixture of hydrobromic acid (48%, 270 ml) and cuprous bromide (2 g) maintained at -7°. The mixture was stirred at -6° for 1 hour and at room temperature for 1.5 hours. The mixture was neutralised with 10M NaOH, treated with sodium metabisulphite, warmed to 60° for 20 min., reneutralised with sodium hydroxide and filtered. The filtrate was extracted with cyclohexane for 13 hours, and the cyclohexane extract was dried over calcium sulphate, filtered and evaporated to give 5-bromo-2-methoxymethyl(1,3,4)thiadiazole (30.35 g) as an oil. (Found: C, 23.0; H, 2.7; Br 38.0; N, 13.5; S, 15.1; C4 H5 BrN2 OS requires C, 23.0; H, 2.4; Br 38.2; N, 13.4; S, 15.3 %).
  • 5
  • [ 15884-86-3 ]
  • [ 431-35-6 ]
  • [ 1294001-16-3 ]
YieldReaction ConditionsOperation in experiment
47% In 1,2-dimethoxyethane at 20 - 80℃; for 24h; 2.2 2.2 Synthesis of 2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1 - bJ[1 ,3,4]thiadiazole a28.Bromotrifluoroacetone (478 g, 1.05 eq) is added on a suspension of 5- (methoxymethyl)-1 ,3,4-thiadiazol-2-amine a25 (346 g, 1 eq) in 1 ,2-dimethoxyethane (6 I) at 20°C. The reaction mixture is heated to 80°C until maximum conversion (<24 h). Water (4 I) is added to the reaction mixture at 32°C and the expected compound crystallized out of the reaction mixture. The crystalline suspension is cooled to 10°C to complete the crystallization process, filtered and the crystalline precipitate is washed with water (1 ,5 I) to afford 266 g of pure 2-(methoxymethyl)-6- (trifluoromethyl)imidazo[2, 1 -b][1 ,3,4]thiadiazole a28.Yield: 47 %.LC-MS (MH+): 238.
47% In 1,2-dimethoxyethane at 20 - 80℃; for 24h; 1.1 1.1 Synthesis of 2-(methoxymethyl)-6-(trifluoromethyl)imiclazo[2,1-b][1 ,3,4]thia- diazole a2.Bromotrifluoroacetone (478 g, 2.5 mol, 1.05 eq) is added on a suspension of 5- (methoxymethyl)-1 ,3,4-thiadiazol-2-amine a1 (346 g, 2.4 mol, 1 eq) in 1 ,2- dimethoxyethane (6 I) at 20°C. The reaction mixture is heated to 80°C until maximum conversion (<24 h). Water (4 I) is added to the reaction mixture at 32°C and the expected compound crystallized out of the reaction mixture. The crystalline suspension is cooled to 10°C to complete the crystallization process, filtered and the crystalline precipitate is washed with water (1 ,5 I) to afford 266 g of pure 2-(methoxymethyl)-6- (trifluoromethyl)imidazo[2,1 -b][1 ,3,4]thiadiazole a2.Yield: 47 %.LC-MS (MH+): 238.
47% In 1,2-dimethoxyethane; water at 80℃; for 24h; 1.1 1.1 Synthesis of 2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazole VIII. 3-Bromo-1,1,1-trifluoroacetone (CAS: 431-35-6, 478 g, 2.5 mol, 1.05 eq) is added on a suspension of 5-(methoxymethyl)-1,3,4-thiadiazol-2-amine (CAS: 15884-86-33, 46 g, 2.4 mol, 1 eq) in 1,2-dimethoxyethane (6 I) at 20°C. The reaction mixture is heated to 80°C until maximum conversion (<24 h). Water (4 I) is added to the reaction mixture at 32°C and the expected compound crystallized out of the reaction mixture. The crystalline suspension is cooled to 10°C to complete the crystallization process, filtered and the crystalline precipitate is washed with water (1,5 I) to afford 266 g of pure 2- (methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazole VIII. Yield: 47 %. LC-MS (MH+): 238.
  • 6
  • [ 15884-86-3 ]
  • [ 24424-99-5 ]
  • [ 1294001-20-9 ]
YieldReaction ConditionsOperation in experiment
88.1% With dmap In dichloromethane at 20℃; 3.1 3.1 Synthesis of tert-butyl [5-(methoxymethyl)-1 ,3,4-thiadiazol-2-yl]carbamate a31.To a suspension of 5-(methoxymethyl)-1 ,3,4-thiadiazol-2-amine a25 (100 g, 0.69 mol, 1 eq) in dichloromethane (1 I) at room temperature is added, successively and each in one portion, di-tert-butyl dicarbonate (132 g, 0.76 mol, 1.1eq,) and N,N-dirnethylamino- pyridine (8.35 g, 0.069 mol, 0.1 eq). After overnight stirring at room temperature, the reaction mixture is washed with 1 N HCI (pH 5) to remove N,N-dimethylaminopyridine. The solvent is then removed under reduced pressure and the residue is recrystallized from di-isopropyl ether to afford 148.9 g of pure tert-butyl [5-(methoxymethyl)-1 ,3,4- thiadiazol-2-yl]carbamate a31.Yield: 88.1 %.LC-MS (MH+): 246.
88% With dmap In dichloromethane at 20℃; 2.1 2.1 Synthesis of tert-butyl [5-(methoxymethyl)-1 ,3,4-thiadiazol-2-yl]carbamate a13. To a suspension of 5-(methoxymethyl)-1 ,3,4-thiadiazol-2-amine a1 (100 g, 0.69 mol, 1 eq) in dichloromethane (1 I) at room temperature are added, successively and each in one portion, di-tert-butyl dicarbonate (132 g, 0.76 mol, 1.1 eq,) and N,N-dimethylamino- pyridine (8.35 g, 0.069 mol, 0.1 eq). After overnight stirring at room temperature, the reaction mixture is washed with 1 N HCI (pH 5) to remove N,N-dimethylaminopyridine. The solvent is removed under reduced pressure and the residue is recrystallized from di-isopropyl ether to afford 148.9 g of pure tert-butyl [5-(methoxymethyl)-1 ,3,4-thiadiazol-2-yl]carbamate a13.Yield: 88 %. LC-MS (MH+): 246.
88% With dmap In dichloromethane at 20℃; 2.1 2.1 Synthesis of tert-butyl [5-(methoxymethyl)- ,3,4-thiadiazo.-2-y.]carbamate a4. To a suspension of 5-(methoxymethyl)-1 ,3,4-thiadiazol-2-amine a1 (100 g, 0.69 mol, 1 eq) in dichloromethane (1 I) at room temperature are added, successively and each in one portion, di-tert-butyl dicarbonate (132 g, 0.76 mol, 1.1 eq,) and N,N-dimethylamino- pyridine (8.35 g, 0.069 mol, 0.1 eq). After overnight stirring at room temperature, the reaction mixture is washed with 1 N HCI (pH 5) to remove Ν,Ν-dimethylaminopyridine. The solvent is removed under reduced pressure and the residue is recrystallized from di-isopropyl ether to afford 148.9 g of pure tert-butyl [5-(methoxymethyl)-1 ,3,4-thiadiazol- 2-yl]carbamate a4.Yield: 88 %.LC-MS (MH+): 246
88% With dmap In dichloromethane at 20℃; 2.1 2.1 Synthesis of tert-butyl [5-(methoxymethyl)-1,3,4-thiadiazol-2-yl]carbamate XIV. To a suspension of 5-(methoxymethyl)-1,3,4-thiadiazol-2-amine (CAS: 15884-86-33, 100 g, 0.69 mol, 1 eq) in dichloromethane (1 I) at room temperature are added, successively and each in one portion, di-tert-butyl dicarbonate (132 g, 0.76 mol, 1.1 eq,) and N,N-dimethylamino-pyridine (8.35 g, 0.069 mol, 0.1 eq). After overnight stirring at room temperature, the reaction mixture is washed with 1 N HCI (pH 5) to remove N,N- dimethylaminopyridine. The solvent is removed under reduced pressure and the residue is recrystallized from di-isopropyl ether to afford 148.9 g of pure tert-butyl [5- (methoxymethyl)-l,3,4-thiadiazol-2-yl]carbamate XIV. Yield: 88 %. LC-MS (MH+): 246.

  • 7
  • [ 15884-86-3 ]
  • [ 98-74-8 ]
  • [ 524676-61-7 ]
YieldReaction ConditionsOperation in experiment
91% In pyridine at 20℃; for 2h; To a solution of 5-(methoxymethyl)-1,3,4-thiadiazol-2-amine (500mg, 3.444mmol) in pyridine (5mL) was added 4-nitrobenzene-l-sulfonyl chloride (1.5g, 6.888mmol). The mixture was stirred at RT for two hours. The solvent was removed under reduced pressure to give a solid. The solid was purified by column chromatography to give N-(5- (methoxymethyl)-l,3,4-thiadiazol-2-yl)-4-nitrobenzenesulfonamide (l .Og, 91%). MS (ESI) m/z 329 [M-H]~.
  • 8
  • [ 15884-86-3 ]
  • [ 431-35-6 ]
  • [ CAS Unavailable ]
YieldReaction ConditionsOperation in experiment
47% In 1,2-dimethoxyethane at 20 - 80℃; 1.1 Example 1. Synthesis of r2-(methoxymethyl)-6-(trifluoromethyl)imidazor2,1- blf1.3.41thiadiazol-5-vHmethanol a3.1.1 Synthesis of 2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1 -b][1 ,3,4]thiadia- zole a2.Bromotrifluoroacetone (478 g, 2.5 mol, 1.05 eq) is added on a suspension of 5- (methoxymethyl)-1 ,3,4-thiadiazol-2-amine a1 (346 g, 2.4 mol, 1 eq) in 1 ,2- dimethoxyethane (6 I) at 20°C. The reaction mixture is heated to 80°C until maximum conversion (<24 h). Water (4 I) is added to the reaction mixture at 32°C and the expected compound crystallized out of the reaction mixture. The crystalline suspension is cooled to 10°C to complete the crystallization process, filtered and the crystalline precipitate is washed with water (1 ,5 I) to afford 266 g of pure 2-(methoxymethyl)-6- (trifluoromethyl)imidazo[2,1-b][1 ,3,4]thiadiazole a2.Yield: 47 %.LC-MS (MH+): 238.
  • 9
  • [ 15884-86-3 ]
  • [ 5470-18-8 ]
  • [ 1420066-32-5 ]
YieldReaction ConditionsOperation in experiment
20% With N-ethyl-N,N-diisopropylamine In toluene at 120℃; for 16h; Sealed tube; 4.6. General procedure for synthesis of triazopyridines 7 General procedure: A mixture of 6 (1.55 mmol), 2 (0.77 mmol), and i-Pr2NEt(1.55 mmol) in toluene (unless otherwise stated) (0.77 ml) was stirred at 120 °C in a sealed tube for 16 h. The mixture was allowed to cool to room temperature. Purification method A: the mixture was concentrated and the residue was purified by reverse phase automatedpreparative HPLC. Purification method B: the mixture was concentrated and the residue was purified by flash column chromatography (SiO2). Purification method C: the mixture was diluted(DCM), washed (satd Na2CO3), dried (filtered through a Biotage phase separator), and concentrated. The residue was purified by reverse phase automated preparative HPLC.
  • 10
  • [ 15884-86-3 ]
  • [ 1493-27-2 ]
  • [ 1420066-22-3 ]
YieldReaction ConditionsOperation in experiment
29% With N-ethyl-N,N-diisopropylamine In 1-methyl-pyrrolidin-2-one at 140℃; for 16h; Sealed tube; 4.4. General procedure for synthesis of triazoles 4 General procedure: A mixture of 1 (1.55 mmol, unless otherwise stated), 2 (0.77 mmol), and i-Pr2NEt (1.55 mmol) in NMP (0.77 mL) was stirred at 140 °C in a sealed tube for 16 h. The mixture was allowed to cool to room temperature, diluted (DCM), washed (satd Na2CO3), dried (filtered through a Biotage phase separator), and concentrated. Purification method A: the residue was purifiedby reverse phase automated preparative HPLC. Purification method B: the residue was purified by flash column chromatography (SiO2).
  • 11
  • [ 15884-86-3 ]
  • [ 104-88-1 ]
  • [ CAS Unavailable ]
YieldReaction ConditionsOperation in experiment
In toluene at 120℃; Molecular sieve; Sealed tube;
In toluene at 120℃; Molecular sieve; Sealed tube; 4.1.1. Typical experimental procedure for ethers 1-7, 11-20 General procedure: A screw-capped V-shaped vial (2.0 mL) was charged with 2-aminothiazole (0.36 mmol, 1.0 equiv), aldehyde (0.40 mmol, 1.1equiv), freshly activated 4 Å molecular sieves (300 mg) and dry toluene(1.5 mL). The vial was capped with a pressure cap and stored at 120 °C for 14-24 h until complete consumption of 2-aminothiazole (monitoredby 1H NMR). The resulting mixture containing imine was cooled to room temperature and the solvent was removed under reduced pressure. Under inert atmosphere, the residue was redissolved in dry toluene(1 mL) and then CuOTf*C6H6 (18 mg, 0.036 mmol, 10 mol %), Cu(OTf)2 (13 mg, 0.036 mmol, 10 mol %), alkyne (0.72 mmol, 2 equiv) and 4 Å molecular sieves (100 mg) were added. The reaction mixture was additionally stirred in the vial capped with a pressure cap at 120 °C for 2 h. After the completion of the reaction, the mixture was filtered through a plug of neutral aluminum oxide (eluent - EtOAc). The filtrate was concentrated under reduced pressure to give a crude material,which was purified by column chromatography on silica gel (eluentEt3N:EtOAc/petroleum ether) or neutral aluminum oxide (eluent EtOAc/petroleum ether) to give product.
  • 12
  • [ 15884-86-3 ]
  • [ 883233-85-0 ]
  • [ 1294001-18-5 ]
YieldReaction ConditionsOperation in experiment
40% In N,N-dimethyl-formamide at 100℃; 1.1.7 To a solution of 5-(methoxymethyl)-1 ,3,4-thiadiazol-2-amine (CAS: 15884-86-3, 1.0 eq., 6.5 g, 45 mmol) in DMF (100 ml_), at 100°C, was added dropwise a solution of 3-bromo- 1 ,1-difluoro-propan-2-one (CAS: 883233-85-0, 1.05 eq., 8.1 g, 47 mmol) in DMF (5 ml_). The reaction mixture was heated at 100°C during 3 h and the completion was checked by LC/MS. A saturated aqueous solution of NaHCC>3 was added and the organic layer was extracted with ethyl acetate (three times). The combined organic layers were washed with water (five times), dried over MgSCU, filtered and evaporated to dryness to give a brown solid (7.6 g). The crude was purified by flash chromatography Biotage Isolera Four (100 g KP-SNAP silica gel column in a gradient of 0% to 5% methanol in dichloromethane over 12 CV) and the pure fractions were combined and evaporated under high vacuum to give 6-(difluoromethyl)-2-(methoxymethyl)imidazo[2,1- b][1 ,3,4]thiadiazole VII (3.95 g, 17.8 mmol) as an orange solid. Yield: 40% LC/MS: [M+H]+ = 220.2 1H NMR (400 MHz, DMSO-c/6): δ 8.53 (t, J = 2.2 Hz, 1 H), 7.01 (t, J = 54.6 Hz, 1 H), 4.83 (s, 2H), 3.43 (s, 3H).
40% In N,N-dimethyl-formamide at 100℃; for 3h; 2.1.5 1.5 Synthesis of 6-(difluoromethyl)-2-(methoxymethyl)imidazo[2, 1 b][1 ,3,4]thiadiazole VII To a solution of 5-(methoxymethyl)-1 ,3,4-thiadiazol-2-amine VI (CAS: 15884-86-3, 1 .0 eq., 6.5 g, 45 mmol) in DMF (100 ml_), at 100°C, was added dropwise a solution of 3- bromo-1 , 1 -difluoro-propan-2-one (CAS: 883233-85-0, 1.05 eq., 8.1 g, 47 mmol) in DMF (5 ml_). The reaction mixture was heated at 100°C during 3 h and the completion was checked by LC/MS. A saturated aqueous solution of NaHC03 was added and the organic layer was extracted with ethyl acetate (three times). The combined organic layers were washed with water (five times), dried over MgS04, filtered and evaporated to dryness to give a brown solid (7.6 g). The crude was purified by flash chromatography Biotage Isolera Four (100 g KP-SNAP silica gel column in a gradient of 0% to 5% methanol in dichloromethane over 12 CV) and the pure fractions were evaporated under high vacuum to give 6-(difluoromethyl)-2-(methoxymethyl)imidazo[2, 1 - b][1 ,3,4]thiadiazole VII (3.95 g, 17.8 mmol) as an orange solid. Yield: 40% LC/MS: [M+H]+ = 220.2 1H NMR (400 MHz, DMSO-cfe): δ 8.53 (t, J = 2.2 Hz, 1 H), 7.01 (t, J = 54.6 Hz, 1 H), 4.83 (s, 2H), 3.43 (s, 3H).
40% In water; N,N-dimethyl-formamide at 100℃; for 3h; C.1 C.1. Synthesis of 6-(difluoromethyl)-2-(methoxymethyl)imidazo[2,1-b][1,3,4]thiadiazole VI To a solution of 5-(methoxymethyl)-1,3,4-thiadiazol-2-amine (CAS: 15884-86-3, 1.0 eq., 6.5 g, 45 mmol) in DMF (100 ml_), at 100°C, was added dropwise a solution of 3-bromo- 1,1-difluoro-propan-2-one (CAS: 883233-85-0, 1.05 eq., 8.1 g, 47 mmol) in DMF (5 ml_). The reaction mixture was heated at 100°C during 3 h and the completion was checked by LC/MS. A saturated aqueous solution of NaHCC>3 was added and the organic layer was extracted with ethyl acetate (three times). The combined organic layers were washed with water (five times), dried over MgS04, filtered and evaporated to dryness to give a brown solid (7.6 g). The crude was purified by flash chromatography Biotage Isolera Four (100 g KP-SNAP silica gel column in a gradient of 0% to 5% methanol in dichloromethane over 12 CV) and the pure fractions were combined and evaporated under high vacuum to give 6-(difluoromethyl)-2-(methoxymethyl)imidazo[2,1- b][1,3,4]thiadiazole VI (3.95 g, 17.8 mmol) as an orange solid. Yield: 40% LC/MS: [M+H]+ = 220.2 1H NMR (400 MHz, DMSO-de): d 8.53 (t, J = 2.2 Hz, 1H), 7.01 (t, J = 54.6 Hz, 1H), 4.83 (s, 2H), 3.43 (s, 3H).
  • 13
  • [ 15884-86-3 ]
  • [ 598-31-2 ]
  • [ 2353501-43-4 ]
YieldReaction ConditionsOperation in experiment
52% In N,N-dimethyl-formamide at 100℃; for 3h; 1.1 1.1 Synthesis of 2-(methoxymethyl)-6-methyl-imidazo[2, 1 -b][1 ,3,4]thiadiazole II To a solution of 5-(methoxymethyl)-1 ,3,4-thiadiazol-2-amine I (CAS: 15884-86-3, WO201 1/047860, 1.0 eq., 7.0 g, 48.2 mmol) in DMF (95 ml_), at 100 °C, was added dropwise a solution of bromoacetone (1.0 eq., 4.2 ml_, 46.2 mmol, 97% purity) in DMF (5 mL). The reaction mixture was stirred at 100 °C for 3 h. The reaction mixture was cooled to room temperature (RT) and the solvent was evaporated until dryness under high vacuum to give a brown oil. The crude was purified by flash chromatography Biotage Isolera Four (100 g KP-SNAP silica gel column in a gradient of 0% to 10% methanol in dichloromethane over 14CV) and the pure fractions were evaporated to dryness to give 2-(methoxymethyl)-6-methyl-imidazo[2,1-b][1 ,3,4]thiadiazole II (5.0 g, 25.1 1 mmol) as a yellow/orange solid. (0154) Yield: 52% (0155) LC/MS: [M+H]+ = 184.0 1H NMR (400 MHz, DMSO -cfe): d 8.53 (m, 1 H), 4.76 (s, 2H), 3.40 (s, 3H), 2.25 (d, J = 1 .0 Hz, 3H).
52% In N,N-dimethyl-formamide at 100℃; for 3h; B.1 B.1 Synthesis of 2-(methoxymethyl)-6-methyl-imidazo[2,1-b][1,3,4]thiadiazole IV To a solution of 5-(methoxymethyl)-1,3,4-thiadiazol-2-amine (CAS: 15884-86-3, WO2011/047860, 1.0 eq., 7.0 g, 48.2 mmol) in DMF (95 ml_), at 100°C, was added dropwise a solution of bromoacetone (1.0 eq., 4.2 ml_, 46.2 mmol, 97% purity) in DMF (5 ml_). The reaction mixture was stirred at 100°C for 3 h. The reaction mixture was cooled to room temperature (RT) and the solvent was evaporated until dryness under high vacuum to give a brown oil. The crude was purified by flash chromatography Biotage Isolera Four (100 g KP-SNAP silica gel column in a gradient of 0% to 10% methanol in dichloromethane over 14CV) and the pure fractions were evaporated to dryness to give 2-(methoxymethyl)-6-methyl-imidazo[2,1-b][1,3,4]thiadiazole IV (5.0 g, 25.1 1 mmol) as a yellow/orange solid. Yield: 52% LC/MS: [M+H]+ = 184.0 1H NMR (400 MHz, DMSO-de): d 8.53 (m, 1H), 4.76 (s, 2H), 3.40 (s, 3H), 2.25 (d, J = 1.0 Hz, 3H).
  • 14
  • [ 15884-86-3 ]
  • [ 87867-10-5 ]
  • [ 2353501-44-5 ]
YieldReaction ConditionsOperation in experiment
28% In N,N-dimethyl-formamide at 100 - 110℃; 4.2 . 4.2 B. Synthesis of 2-(methoxymethyl)-6-(trideuteriomethyl)imidazo[2,1- b][1 ,3,4]thiadiazole IX. To a solution of 5-(methoxymethyl)-1 ,3,4-thiadiazol-2-amine | (1.0 eq., 8.0 g, 55.1 mmol) in DMF (100 ml_), at 100 °C, was added dropwise a solution of 1-bromo- 1 ,1 ,3,3,3-pentadeuterio-propan-2-one VIII (1.05 eq., 8.22 g, 57.9 mmol) in DMF (20 ml_). The reaction mixture was stirred at 1 10 °C for 2 h 30. The mixture was then cooled to RT, a saturated solution of NaHCC>3 was added and the solvent was evaporated until dryness. The obtained crude was then diluted in EtOAc, filtered and the filtrate was evaporated until dryness to give a brown oil (9.5 g). The crude was purified by flash chromatography Biotage Isolera Four (100 g KP-SNAP silica gel column in a gradient of 0% to 10% methanol in dichloromethane over 14CV) and the pure fractions were evaporated to dryness to give 2-(methoxymethyl)-6-(trideuteriomethyl)imidazo[2,1- b][1 ,3,4]thiadiazole IX (3.05 g, 15.6 mmol) as a yellow solid. (0190) Yield: 28% (0191) LC/MS: [M+H]+ = 187.2 1H NMR (400 MHz, DMSO-d6) d 7.45 (s, 1 H), 4.70 (s, 2H), 3.48 (s, 3H)
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 15884-86-3 ]

Ethers

Chemical Structure| 1014-25-1

A173741 [1014-25-1]

5-(4-Methoxyphenyl)-1,3,4-thiadiazol-2-amine

Similarity: 0.51

Chemical Structure| 247109-15-5

A499649 [247109-15-5]

5-(3-Methoxyphenyl)-1,3,4-thiadiazol-2-amine

Similarity: 0.50

Amines

Chemical Structure| 64837-53-2

A142073 [64837-53-2]

Ethyl 5-amino-1,3,4-thiadiazole-2-carboxylate

Similarity: 0.77

Chemical Structure| 108-33-8

A710744 [108-33-8]

2-Amino-5-methyl-1,3,4-thiadiazole

Similarity: 0.74

Chemical Structure| 4005-51-0

A232255 [4005-51-0]

1,3,4-Thiadiazol-2-amine

Similarity: 0.55

Chemical Structure| 2937-81-7

A261247 [2937-81-7]

1,3,4-Thiadiazole-2,5-diamine

Similarity: 0.54

Chemical Structure| 2349-67-9

A237933 [2349-67-9]

5-Amino-1,3,4-thiadiazole-2-thiol

Similarity: 0.51

Related Parent Nucleus of
[ 15884-86-3 ]

Thiadiazoles

Chemical Structure| 64837-53-2

A142073 [64837-53-2]

Ethyl 5-amino-1,3,4-thiadiazole-2-carboxylate

Similarity: 0.77

Chemical Structure| 108-33-8

A710744 [108-33-8]

2-Amino-5-methyl-1,3,4-thiadiazole

Similarity: 0.74

Chemical Structure| 4005-51-0

A232255 [4005-51-0]

1,3,4-Thiadiazol-2-amine

Similarity: 0.55

Chemical Structure| 2937-81-7

A261247 [2937-81-7]

1,3,4-Thiadiazole-2,5-diamine

Similarity: 0.54

Chemical Structure| 64837-49-6

A189756 [64837-49-6]

Ethyl 5-chloro-1,3,4-thiadiazole-2-carboxylate

Similarity: 0.52